Suppr超能文献

微环境与肿瘤细胞:肝细胞癌新分子疗法的两个靶点

Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

作者信息

Amicone Laura, Marchetti Alessandra

机构信息

Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy.

出版信息

Transl Gastroenterol Hepatol. 2018 May 2;3:24. doi: 10.21037/tgh.2018.04.05. eCollection 2018.

Abstract

Hepatocellular carcinoma (HCC), is one of the most frequent human cancer and is characterized by a high mortality rate. The aggressiveness appears strictly related to the liver pathological background on which cancer develops. Inflammation and the consequent fibro/cirrhosis, derived from chronic injuries of several origins (viral, toxic and metabolic) and observable in almost all oncological patients, represents the most powerful risk factor for HCC and, at the same time, an important obstacle to the efficacy of systemic therapy. Multiple microenvironmental cues, indeed, play a pivotal role in the pathogenesis, evolution and recurrence of HCC as well as in the resistance to standard therapies observed in most of patients. The identification of altered pathways in cancer cells and of microenvironmental changes, strictly connected in pathogenic feedback loop, may permit to plan new therapeutic approaches targeting tumor cells and their permissive microenvironment, simultaneously.

摘要

肝细胞癌(HCC)是人类最常见的癌症之一,其特点是死亡率高。肿瘤的侵袭性似乎与癌症发生的肝脏病理背景密切相关。炎症以及随之而来的纤维化/肝硬化,源于多种原因(病毒、毒素和代谢)引起的慢性损伤,几乎在所有肿瘤患者中都可观察到,是HCC最强大的危险因素,同时也是全身治疗疗效的重要障碍。事实上,多种微环境信号在HCC的发病机制、进展和复发以及大多数患者对标准治疗的耐药性中都起着关键作用。识别癌细胞中改变的信号通路以及微环境变化(在致病反馈回路中紧密相连),可能有助于同时规划针对肿瘤细胞及其适宜微环境的新治疗方法。

相似文献

1
Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.
Transl Gastroenterol Hepatol. 2018 May 2;3:24. doi: 10.21037/tgh.2018.04.05. eCollection 2018.
3
Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
World J Gastroenterol. 2014 Nov 7;20(41):15018-27. doi: 10.3748/wjg.v20.i41.15018.
4
Hepatitis C virus suppresses Hepatocyte Nuclear Factor 4 alpha, a key regulator of hepatocellular carcinoma.
Int J Biochem Cell Biol. 2016 Sep;78:315-326. doi: 10.1016/j.biocel.2016.07.027. Epub 2016 Jul 29.
6
Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?
World J Gastroenterol. 2016 Jan 7;22(1):50-71. doi: 10.3748/wjg.v22.i1.50.
9
New Tools for Molecular Therapy of Hepatocellular Carcinoma.
Diseases. 2015 Oct 30;3(4):325-340. doi: 10.3390/diseases3040325.
10
Viral non-coding RNA inhibits HNF4α expression in HCV associated hepatocellular carcinoma.
Infect Agent Cancer. 2015 Jul 8;10:19. doi: 10.1186/s13027-015-0014-0. eCollection 2015.

引用本文的文献

1
The role of pioneering transcription factors, chromatin accessibility and epigenetic reprogramming in oncogenic viruses.
Front Microbiol. 2025 Jun 16;16:1602497. doi: 10.3389/fmicb.2025.1602497. eCollection 2025.
2
Achieving tolerance modifies cancer susceptibility profiles in liver transplant recipients.
Cancer Med. 2023 Feb;12(4):5150-5157. doi: 10.1002/cam4.5271. Epub 2022 Oct 7.
3
The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
Front Endocrinol (Lausanne). 2022 Aug 25;13:918869. doi: 10.3389/fendo.2022.918869. eCollection 2022.
5
Exosome-Associated circRNAs as Key Regulators of EMT in Cancer.
Cells. 2022 May 23;11(10):1716. doi: 10.3390/cells11101716.
8
The Role of TGF- Signaling Pathways in Cancer and Its Potential as a Therapeutic Target.
Evid Based Complement Alternat Med. 2021 Jul 22;2021:6675208. doi: 10.1155/2021/6675208. eCollection 2021.

本文引用的文献

1
New Tools for Molecular Therapy of Hepatocellular Carcinoma.
Diseases. 2015 Oct 30;3(4):325-340. doi: 10.3390/diseases3040325.
2
Role of the long non-coding RNA HOTAIR in hepatocellular carcinoma.
Oncol Lett. 2017 Aug;14(2):1233-1239. doi: 10.3892/ol.2017.6312. Epub 2017 Jun 6.
3
The hepatocyte-specific HNF4α/miR-122 pathway contributes to iron overload-mediated hepatic inflammation.
Blood. 2017 Aug 24;130(8):1041-1051. doi: 10.1182/blood-2016-12-755967. Epub 2017 Jun 27.
5
EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Int J Mol Sci. 2017 May 31;18(6):1172. doi: 10.3390/ijms18061172.
6
Systemic therapy for advanced hepatocellular carcinoma: an update.
J Gastrointest Oncol. 2017 Apr;8(2):243-255. doi: 10.21037/jgo.2017.02.01.
9
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验